BWA
KYMR icon

Basecamp Wealth Advisors’s Kymera Therapeutics KYMR Stock Holding History

Basecamp Wealth Advisors’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19
Closed -$1.58K – 1921
2026
Q1 		$1.58K Buy
19
+10
+111% +$792 ﹤0.01% 1451
2025
Q4 		$700 Buy
+9
New +$608 ﹤0.01% 1564

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Basecamp Wealth Advisors's KYMR Position: Q2 2026 in Review

Basecamp Wealth Advisors sold out of Kymera Therapeutics (KYMR) in Q2 2026, closing a stake of 19 shares — an estimated $1.58K sold.

Basecamp Wealth Advisors first reported a position in KYMR in Q4 2025 and held it in 2 quarters. The position peaked at $1.58K in Q1 2026. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Basecamp Wealth Advisors reported no remaining Kymera Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Basecamp Wealth Advisors sold 19 Kymera Therapeutics shares in Q2 2026, an estimated $1.58K.
  • Basecamp Wealth Advisors first reported a position in Kymera Therapeutics in Q4 2025 and held it in 2 quarters.
  • Basecamp Wealth Advisors's Kymera Therapeutics position peaked at $1.58K in Q1 2026.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.